Publications

RECENT EMPLOYEE PUBLICATIONS

  • Hai, Yang; Edwards, Jennifer E.; Van Zandt, Michael C.; Hoffmann, Karl F.; Christianson, David W.  Crystal structure of Schistosoma mansoni arginase, a potential drug target for the treatment of schistosomiasis.  Biochemistry 2014, 53(28), 4671-4684.
  • Van Zandt, M. C. Whitehouse, D. L., Golebiowski, A., Ji, M., Zhang, M., Beckett, R. P., Jagdmann, G. E., Ryder, T., Sheeler, R., Andreoli, M., Conway, B., Mahboubi, K., D’Angelo, G., Mitschler, A., Cousido-Siah, A., Ruiz, F. X., Howard, E., Podjarny, A. D.  and Schroeter, H.  Discovery of (R)-2-Amino-6-borono-2-(2-(piperidin-1-yl)ethyl)hexanoic acid and Congeners as Highly Potent Inhibitors of Human Arginases I and II for Treatment of Myocardial Reperfusion Injury. J. Med. Chem, 2013, 56, 2568-2580.
  • Golebiowski, A., Beckett, R. P., Van Zandt, M. C., Ji, M., Whitehouse, D., Ryder, T., Jagdmann, G. E., Andreoli, M., Mazur, A., Padmanilayam, M., Cousido-Siah, A., Mitschler, A., Ruiz, F. X., Podjarny, A. and Schroeter, H.  2-Substituted-2-Amino-6-Boronohexanoic Acids as Arginase Inhibitors. Bioorg. & Med. Chem.2013, 23, 2027-2030.
  • Zhang, M., Jagdmann, G. E., Van Zandt, M. C., Sheeler, R., Beckett, P. and Schroeter, H.  Chemical Synthesis and Characterization of Epicatechin Glucuronides and Sulfates: Bioanalytical Standards for Epicatechin Metabolite Identification. Journal of Natural Products 2013, 76, 157-169.
  • Mingbao Zhang, G. Erik Jagdmann, Michael Van Zandt, Paul Beckett and Hagen Schroeter. Enantioselective synthesis of orthogonally protected (2R,3R)-(-)-epicatechin derivatives, key intermediates in the do novo chemical synthesis of (-)-epicatechin glucuronides and sulfates. Tetrahedron Asymmetry 2013, 24, 362-373.
  • Adam Golebiowski, Darren Whitehouse, R. Paul Beckett, Michael Van Zandt, Min Koo Ji, Todd Ryder, Erik Jagdmann, Monica Andreoli, Yung Lee, Ryan Sheeler, Bruce Conway, Jacek, Olczak, Marzena Mazur, Wojciech Czestkowski, Wieslawa Piotrowska, Alexandra Cousido-Siah, Andre Mitschler, Francesc X. Ruiz, Alberto Podjarny, Hagen Schroeter. Synthesis of quaternary a-amino acid-based arginase inhibitors via the Ugi reaction. Bioorg. & Med. Chem. Let. 2013, 23, 4837-4841.
  • Mull, E., Van Zandt, M. C., Golebiowski, A., Beckett, R. P., Sharma, P., and Schroeter H.  A versitile approach to the regioselective synthesis of diverse (-)-epicatechin-b-D-glucuronide. Tetrahedron Letters 2012, 53, 1501-1503.
  • Van Zandt, M. C., Doan, B., Sawicki, D. R., Sredy, J. and Podjarny, A. D.   Discovery of [3-(4,5,7-trifluoro-benzothiazol-2-ylmethyl)-pyrrolo[2,3-b]pyridin-1-yl]acetic acids as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complicationsBioorganic & Medicinal Chemistry Letters2009, 19, 2006-2008.
  • Taylor, S. J., Turner, C. M., Elliott, J. I., Mc Daid, J., Reiko, H., Smith, J., Pickering, M. C., Whitehouse, D. L., Cook, H. T., Burnstock, G., Pusey, C. D., Unwin, R. J., Tam, F. W. K. P2X7-Deficiency attenuates renal injury in experimental glomerulonephritis. J. Am. Soc. Nephrol. 2009, 20, 1275-1281.
  • Mahboubi, K., Witman-Jones, T., Adamus, J, E., Letsinger, J., Whitehouse, D., Moorman, A., Sawicki, D., Bergenhem, N., Ross, S. Triglyceride modulation by Acifran analogs:  activity towards the Niacin high and low affinity receptors HM74A and HM74. BioChem. BioPhys. Res. Comm. 2006, 340, 482-490.
  • Johnson, M. P., Barda, D., Britton, T. C., Emkey, R., Hornback, W., Jagdmann, G. E., McKinzie, D., Nisenbaum, E., Tizzano, J., Schoepp, D. D. Metabotropic glutamate 2 receptor potentiators:receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis models. Psychopharmacology2005, 179, 271-283.
  • Van Zandt, M. C., Jones, M. L., Jones, J. H., Gunn, D. E., Flam, B., Sawicki, D. R., Sabetta, A., Carrington, A., Sredy, J., Howard, E., Mitschler, A. and Podjarny, A. D.  Discovery of 3-[(4,5,7-Trifluorobenzothiazol-2-yl)methyl]indole-N-acetic Acid (Lidorestat) and Congeners as Highly Potent and Selective Inhibitors of Aldose Reductase for Treatment of Chronic Diabetic Complications. J. Med. Chem. 2005, 48, 3141-3152.
  • Barda, D., Wang, Z-Q., Britton, T. C., Henry, S. S., Jagdmann, G. E., Coleman, D. S., Johnson, M. P., Andis, S. L., Schoepp, D. D. SAR study of a subtype selective allosteric potentiator of metabotropic glutamate 2 receptor, N-(4-phenoxyphenyl)-N-(3-pyridinylmethyl)ethanesulfonamide.  Bioorg. Med. Chem. Lett. 2004, 14, 3099-3102.
  • Van Zandt, M. C., Sibley, E. O., McCann, E. E., Combs, K. J., Flam, B., Sawicki, D., Sabetta, A., Carrington, A., Sredy, J., Howard, E., Mitschler, A., Chevrier, B. and Podjarny. A.  Design and Synthesis of Novel, Potent and Selective Phenoxyacetic Acid Inhibitors of Aldose Reductase for Treatment of Chronic Diabetic Complications.Bioorg. & Med. Chem.  2004, 12, 5661-5675.
  • Podjarny, A.; Cachau, R. E.; Schneider, T.; Van Zandt, M.; Joachimiak, A.  Subatomic and atomic crystallographic studies of aldose reductase: Implications for inhibitor binding.    Cellular and Molecular Life Sciences 2004, 61, 763-773.
  • Howard, E. I.; Sanishvili, R.; Cachau, R. E.; Mitschler, A.; Chevrier, B.; Barth, P.; Lamour, V.; Van Zandt, M.; Sibley, E.; Bon, C.; Moras, D.; Schneider, T. R.; Joachimiak, A.; Podjarny, A.  Ultrahigh resolution drug design I: Details of interactions in human aldose reductase-inhibitor complex at 0.66 A.    Proteins: Structure, Function, and Bioinformatics 2004, 55, 792-804.
  • Johnson, M. P., Baez, M., Jagdmann, G. E., Britton, T. C., Large, T. H., Callagaro, D. O., Tizzano, J. P., Monn, J. A., Schoepp, D. D. Discovery of allosteric potentiators for the metabotropic glutamate 2 receptor: synthesis and subtype selectivity of N-(4-(2-methoxyphenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-3-ylmethylamine.  J. Med. Chem. 2003, 46, 3189-3192.

JOIN OUR MAILING LIST